Bifogade filer
PDF
Kurs
+12,31%
Likviditet
0,87 MSEK
Kalender
| Est. tid* | ||
| 2025-11-20 | N/A | Årsstämma |
| 2025-11-14 | 09:00 | Kvartalsrapport 2026-Q1 |
| 2025-08-28 | 08:30 | Bokslutskommuniké 2025 |
| 2025-05-22 | 09:00 | Kvartalsrapport 2025-Q3 |
| 2025-03-11 | - | Extra Bolagsstämma 2025 |
| 2025-02-13 | - | Kvartalsrapport 2025-Q2 |
| 2024-11-22 | - | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
| 2024-11-21 | - | Årsstämma |
| 2024-11-15 | - | Kvartalsrapport 2025-Q1 |
| 2024-08-28 | - | Bokslutskommuniké 2024 |
| 2024-05-24 | - | Kvartalsrapport 2024-Q3 |
| 2024-02-22 | - | Kvartalsrapport 2024-Q2 |
| 2023-12-14 | - | Extra Bolagsstämma 2024 |
| 2023-11-24 | - | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
| 2023-11-23 | - | Årsstämma |
| 2023-11-17 | - | Kvartalsrapport 2024-Q1 |
| 2023-08-28 | - | Bokslutskommuniké 2023 |
| 2023-05-26 | - | Kvartalsrapport 2023-Q3 |
| 2023-05-17 | - | Extra Bolagsstämma 2023 |
| 2023-02-23 | - | Kvartalsrapport 2023-Q2 |
| 2022-11-25 | - | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
| 2022-11-24 | - | Årsstämma |
| 2022-11-11 | - | Kvartalsrapport 2023-Q1 |
| 2022-08-26 | - | Bokslutskommuniké 2022 |
| 2022-05-20 | - | Kvartalsrapport 2022-Q3 |
| 2022-02-25 | - | Kvartalsrapport 2022-Q2 |
| 2021-11-26 | - | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
| 2021-11-25 | - | Årsstämma |
| 2021-11-11 | - | Kvartalsrapport 2022-Q1 |
| 2021-08-27 | - | Bokslutskommuniké 2021 |
| 2021-06-17 | - | Extra Bolagsstämma 2022 |
| 2021-05-21 | - | Kvartalsrapport 2021-Q3 |
| 2021-03-02 | - | Extra Bolagsstämma 2021 |
| 2021-02-26 | - | Kvartalsrapport 2021-Q2 |
| 2020-11-27 | - | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
| 2020-11-26 | - | Årsstämma |
| 2020-11-12 | - | Kvartalsrapport 2021-Q1 |
| 2020-08-28 | - | Bokslutskommuniké 2020 |
| 2020-05-22 | - | Kvartalsrapport 2020-Q3 |
| 2020-02-28 | - | Kvartalsrapport 2020-Q2 |
| 2019-11-22 | - | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
| 2019-11-21 | - | Årsstämma |
| 2019-11-08 | - | Kvartalsrapport 2020-Q1 |
| 2019-08-30 | - | Bokslutskommuniké 2019 |
| 2019-05-17 | - | Kvartalsrapport 2019-Q3 |
| 2019-02-15 | - | Kvartalsrapport 2019-Q2 |
| 2018-11-16 | - | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
| 2018-11-15 | - | Årsstämma |
| 2018-11-09 | - | Kvartalsrapport 2019-Q1 |
| 2018-08-30 | - | Bokslutskommuniké 2018 |
| 2018-05-18 | - | Kvartalsrapport 2018-Q3 |
| 2018-02-16 | - | Kvartalsrapport 2018-Q2 |
| 2017-11-10 | - | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
| 2017-11-09 | - | Årsstämma |
| 2017-11-02 | - | Kvartalsrapport 2018-Q1 |
| 2017-08-18 | - | Bokslutskommuniké 2017 |
| 2017-05-12 | - | Kvartalsrapport 2017-Q3 |
| 2017-02-10 | - | Kvartalsrapport 2017-Q2 |
| 2017-01-19 | - | Extra Bolagsstämma 2018 |
| 2016-11-18 | - | Kvartalsrapport 2017-Q1 |
| 2016-11-11 | - | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
| 2016-11-10 | - | Årsstämma |
| 2016-08-19 | - | Bokslutskommuniké 2016 |
| 2016-05-13 | - | Kvartalsrapport 2016-Q3 |
| 2016-02-12 | - | Kvartalsrapport 2016-Q2 |
| 2015-11-13 | - | Kvartalsrapport 2016-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Hamlet BioPharma has appointed Elisabeth Parker, PhD to strengthen the business development expertise in the company. Dr. Parker has 25 years' experience of R&D, partnering and commercialization of therapeutics, diagnostics and enabling technologies. Dr. Parker leaves her current position as Senior Investment Advisor Healthcare and Life Sciences at Business Sweden to take up the 80% position with Hamlet BioPharma. Elisabeth Parker will leave the board of Hamlet Biopharma at the upcoming extraordinary general meeting as she now takes on a management role in the company.
Dr Parker received a PhD in 1998 from the Medical Faculty, Lund University, Sweden. More recently, she has served as Director of Business Development at the Immunotherapy company Macrophage Pharma, Business development executive at the development and commercialization arm of Cancer Research UK (CRUK) and Non-Executive Board Director of Azeria Ltd and Arquer diagnostics Ltd.
This recruitment strengthens the business development process of Hamlet BioPharma and adds high profile pharma competence and active international networks, says Catharina Svanborg, CEO of Hamlet BioPharma.
For more information, please contact:
Catharina Svanborg, CEO.
Phone: +46 709 42 65 49
E-mail: catharina.svanborg@hamletbiopharm